Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2021-03-31 Board/Management Inform…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER
Board/Management Information Classification · 100% confidence The document is an announcement from Simcere Pharmaceutical Group Limited regarding the resignation of an executive director and chief operating officer. It contains no financial data, no report or presentation, and no mention of voting results or legal proceedings. The content is specifically about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is a direct announcement, not a report or certification.
2021-03-31 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report Classification · 95% confidence The document is titled 'Announcement of Annual Results for the Year Ended December 31, 2020' and contains detailed financial highlights including revenue, profit, earnings per share, and R&D costs for the full fiscal year 2020. It also includes a comprehensive business review, industry review, and management discussion and analysis sections. The length is substantial (15,000 characters), and the content includes actual financial data and analysis rather than just an announcement or summary. The document is clearly a full annual report covering company activity and financial performance for the year ended December 31, 2020. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-03-25 English
Revised Terms of Reference of the Strategy Committee
Governance Information Classification · 100% confidence The document is titled 'Revised Terms of Reference of the Strategy Committee' and details the composition, duties, meeting procedures, and governance of a board committee. It references the Listing Rules and Articles of Association, focusing on governance structure and committee responsibilities. There is no financial data, earnings information, or regulatory filings related to financial results. The content is about internal governance practices and committee terms, which aligns with Governance Information filings. The document length is 9583 characters, indicating a substantive report rather than a brief announcement. Therefore, the appropriate classification is Governance Information (CGR).
2021-03-25 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL OF PHASE III CLINICAL TRIAL APPLICATION FOR ADDITION OF NEW INDICATION FOR ENDOSTAR BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the approval of a Phase III clinical trial application for a new indication of their drug Endostar by the National Medical Products Administration of China. It provides detailed information about the clinical trial, the drug, and the company's business focus. There are no financial statements, earnings data, or regulatory certifications. The content is a business update related to clinical development and regulatory approval, not a financial report or management discussion. It is not an announcement of voting results, capital changes, or legal proceedings. The document is a voluntary business update announcement, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-03-21 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Simcere Pharmaceutical Group Limited stating the date of a board meeting to consider and approve the annual results for the year ended December 31, 2020, and the recommendation on the payment of a final dividend. It does not contain any financial data or detailed report content but merely informs about the upcoming board meeting and the agenda. The document length is only 1530 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'Menu vs Meal' rule, such a short notice about a meeting to approve annual results is classified as a Regulatory Filing (RNS) rather than the Annual Report (10-K) or Earnings Release (ER).
2021-03-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
Major Shareholding Notification Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 28/02/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for Simcere Pharmaceutical Group Limited. The content focuses on share capital changes and confirmations related to securities issued during the month. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory return concerning share capital movements, which fits the category of Major Shareholding Notification or similar. However, since it is a monthly return on movements in securities, it aligns best with the category Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or share capital movements. The document is not an announcement of a report but a detailed regulatory filing on share capital movements. Therefore, the most appropriate classification is MRQ with high confidence.
2021-03-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.